Prostate cancer and its management have been intensely debated for years.
Recommendations range from ardent support for active screening and immediate treatment to resolute avoidance of screening and active surveillance. There is a growing body of level I evidence establishing a clear survival advantage for treatment of subsets of patients with clinically localized prostate cancer. This chapter presents a review of these randomized controlled trials. We argue that an understanding of this literature is relevant not only to those considering active surveillance but also to those evaluating the merits of screening. In addition, a number of important evidence-based conclusions concerning what should and should not be done can be gleaned from these trials.
Written by:
Roach M 3rd, Thomas K. Are you the author?
UCSF-Helen Diller Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, Suite H1031, San Francisco, CA 94143-1708.
Reference: J Natl Cancer Inst Monogr. 2012;2012(45):221-9.
doi: 10.1093/jncimonographs/lgs039
PubMed Abstract
PMID: 23271777
UroToday.com Prostate Cancer Section
